MCID: CNN002
MIFTS: 40

Cannabis Abuse malady

Categories: Mental diseases

Aliases & Classifications for Cannabis Abuse

Summaries for Cannabis Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cannabis despite negative consequences.

MalaCards based summary : Cannabis Abuse, also known as marijuana abuse, is related to cannabis dependence and schizophrenia. An important gene associated with Cannabis Abuse is CNR1 (Cannabinoid Receptor 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and CREB Pathway. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include testes, thyroid and brain, and related phenotypes are behavior/neurological and no phenotypic analysis

Related Diseases for Cannabis Abuse

Graphical network of the top 20 diseases related to Cannabis Abuse:



Diseases related to Cannabis Abuse

Symptoms & Phenotypes for Cannabis Abuse

MGI Mouse Phenotypes related to Cannabis Abuse:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.43 BDNF CHRNA3 CHRNA5 CHRNB3 CNR1 NGF
2 no phenotypic analysis MP:0003012 8.92 BDNF CHRNA3 CNR1 NGF

Drugs & Therapeutics for Cannabis Abuse

Drugs for Cannabis Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 388)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
2
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4,Phase 1,Phase 2 34841-39-9, 34911-55-2 444
4
Risperidone Approved, Investigational Phase 4,Phase 1 106266-06-2 5073
5
Dronabinol Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1972-08-3 16078 2978
6
Nicotine Approved Phase 4,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
7
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
8
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
9
Clozapine Approved Phase 4 5786-21-0 2818
10
Fluoxetine Approved, Vet_approved Phase 4,Phase 2 54910-89-3 3386
11
Budesonide Approved Phase 4 51333-22-3 63006 5281004
12
Tranexamic Acid Approved Phase 4 1197-18-8 5526
13
Menthol Approved Phase 4,Phase 2 2216-51-5 16666
14
Levodopa Approved Phase 4 59-92-7 6047
15
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
16
Physostigmine Approved Phase 4 57-47-6 5983
17
Haloperidol Approved Phase 4 52-86-8 3559
18
Ondansetron Approved Phase 4 99614-02-5 4595
19
Sulfamethoxazole Approved Phase 4 723-46-6 5329
20
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
21
Lorazepam Approved Phase 4,Phase 1 846-49-1 3958
22
Cefazolin Approved Phase 4 25953-19-9 656510 33255
23
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
24
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
25
Cefdinir Approved Phase 4 91832-40-5 6915944
26
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
27
Ledipasvir Approved Phase 4 1256388-51-8 67505836
28
leucovorin Approved, Nutraceutical Phase 4,Phase 2 58-05-9 54575, 6560146 143
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
30
decanoic acid Experimental Phase 4 334-48-5 2969
31 Quetiapine Fumarate Phase 4,Phase 3,Phase 2,Phase 1 111974-72-2
32 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33
Serotonin Phase 4,Phase 2,Phase 1 50-67-9 5202
34 Muscarinic Antagonists Phase 4,Phase 1
35 Cholinergic Agents Phase 4,Phase 2,Phase 1
36 Folic Acid Antagonists Phase 4,Phase 2
37 Cholinergic Antagonists Phase 4,Phase 1
38 Serotonin Agents Phase 4,Phase 2,Phase 1
39 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Serotonin Antagonists Phase 4,Phase 1
41 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 1
42 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1
43 GABA Modulators Phase 4,Phase 2,Phase 3,Phase 1
44 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
47 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 1,Phase 2
48 Hallucinogens Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
49 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 1,Phase 2
50 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 487)
id Name Status NCT ID Phase
1 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
2 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4
3 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4
4 Nicotine Patch for Marijuana Withdrawal Completed NCT01400243 Phase 4
5 Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania Completed NCT00393978 Phase 4
6 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4
7 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4
8 Substance Dependent Teens - Impact of Treating Depression Study 1 - 1 Completed NCT00061113 Phase 4
9 Role of Tranexamic Acid Versus Uterine Cooling at Caesarean Section Completed NCT02780245 Phase 4
10 The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis Completed NCT02696850 Phase 4
11 The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain Completed NCT01598207 Phase 4
12 Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes Completed NCT00510276 Phase 4
13 Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC) Recruiting NCT03056482 Phase 4
14 Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome Recruiting NCT03090620 Phase 4
15 Progesterone and Brain Imaging Study Recruiting NCT01954966 Phase 4
16 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4
17 Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753) Recruiting NCT02560389 Phase 4
18 Clozapine for Cannabis Use in Schizophrenia Active, not recruiting NCT01639872 Phase 4
19 Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs Active, not recruiting NCT02347345 Phase 4
20 Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE Terminated NCT00687609 Phase 4
21 Brief Counseling to Reduce Injuries Among Emergency Department Patients Who Report Alcohol and Substance Use Unknown status NCT00547963 Phase 2, Phase 3
22 CANDIS-II: Evaluation of the Cognitive-behavioral Treatment Programme CANDIS Unknown status NCT00673647 Phase 3
23 A Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers Unknown status NCT00484367 Phase 2, Phase 3
24 Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults Unknown status NCT00218114 Phase 3
25 Teen Marijuana Check-Up Completed NCT01109563 Phase 3
26 Vaporized Cannabis and Spinal Cord Injury Pain Completed NCT01555983 Phase 2, Phase 3
27 Nabilone & Marijuana Addiction Completed NCT01025700 Phase 2, Phase 3
28 A Brief Marijuana Intervention for Adolescent Women - 1 Completed NCT00227864 Phase 3
29 Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment Completed NCT01675661 Phase 3
30 Combined Pharmacotherapy for Cannabis Dependency Completed NCT01020019 Phase 2, Phase 3
31 Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Completed NCT01776970 Phase 2, Phase 3
32 A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury Completed NCT01606202 Phase 3
33 A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin Completed NCT01606176 Phase 3
34 A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain Completed NCT01606189 Phase 3
35 Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain Completed NCT00675948 Phase 3
36 A Study of the Long-term Safety of Sativex Use Completed NCT01606137 Phase 3
37 Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders Completed NCT01979133 Phase 3
38 A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis Completed NCT00678795 Phase 3
39 A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy Completed NCT00674609 Phase 3
40 A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia. Completed NCT00711880 Phase 3
41 A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis. Completed NCT00711646 Phase 3
42 Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS Completed NCT00391079 Phase 3
43 "Effectiveness of a Brief Intervention for Substances Consumption Linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A Randomized Control Trial in Chilean Primary Care." Completed NCT01573416 Phase 3
44 Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling Completed NCT00221975 Phase 3
45 Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR) Completed NCT00197262 Phase 3
46 Study In Adults And Adolescents With Seasonal Allergic Rhinitis. Completed NCT00225823 Phase 3
47 Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action Completed NCT00118729 Phase 3
48 Study of GW685698X In Patients With Seasonal Allergic Rhinitis Completed NCT00363740 Phase 3
49 Study In Adults And Adolescents With Seasonal Allergic Rhinitis Completed NCT00115622 Phase 3
50 A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Completed NCT01610687 Phase 3

Search NIH Clinical Center for Cannabis Abuse

Genetic Tests for Cannabis Abuse

Anatomical Context for Cannabis Abuse

MalaCards organs/tissues related to Cannabis Abuse:

39
Testes, Thyroid, Brain

Publications for Cannabis Abuse

Articles related to Cannabis Abuse:

(show top 50) (show all 99)
id Title Authors Year
1
Transverse myelitis associated with heroin and cannabis abuse: a new issue from the past. ( 27003705 )
2016
2
Assessing the structure of the CAST (Cannabis Abuse Screening Test) in 13 European countries using multigroup analyses. ( 27981662 )
2016
3
Shifting the Paradigm: Adolescent Cannabis Abuse and the Need for Early Intervention. ( 26800275 )
2016
4
The Cannabis Abuse Screening Test (CAST) revisited: examining measurement invariance by age. ( 27723274 )
2016
5
Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients. ( 26935430 )
2016
6
Concomitant cannabis abuse/dependence in patients treated with opioids for non-cancer pain. ( 26246069 )
2015
7
Methamphetamine and cannabis abuse in adolescence: a quasi-experimental study on specific and long-term neurocognitive effects. ( 25636791 )
2015
8
Commentary on Kosty et al. (2015): Cannabis abuse from one generation to the next-a heightened vulnerability in women? ( 26094497 )
2015
9
Authors' Response to "Parental Cannabis Abuse and Accidental Intoxication in Children: Prevention by Detecting Neglectful Situations and At-Risk Families". ( 26427950 )
2015
10
The influence of age and gender on the likelihood of endorsing cannabis abuse/dependence criteria. ( 25481449 )
2015
11
Sex-dependent vulnerability to cannabis abuse in adolescence. ( 25941498 )
2015
12
Cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia. ( 25716487 )
2015
13
Properties of the Cannabis Abuse Screening Test (CAST) in the general population. ( 26077195 )
2015
14
Cannabinoid hyperemesis should be recognised as an effect of chronic cannabis abuse. ( 25120899 )
2014
15
Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. ( 24682777 )
2014
16
Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. ( 24788457 )
2014
17
The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. ( 24990397 )
2014
18
Cannabis abuse and age at onset in schizophrenia patients with large, rare copy number variants. ( 24685822 )
2014
19
Parental Cannabis Abuse and Accidental Intoxications in Children: Prevention by Detecting Neglectful Situations and At-Risk Families. ( 25407034 )
2014
20
Predicting cannabis abuse screening test (CAST) scores: a recursive partitioning analysis using survey data from Czech Republic, Italy, the Netherlands and Sweden. ( 25264894 )
2014
21
Functioning of Cannabis Abuse and Dependence Criteria Across Two Different Countries: The United States and The Netherlands. ( 25363693 )
2014
22
Long-term cannabis abuse and early-onset cannabis use increase the severity of cocaine withdrawal during detoxification and rehospitalization rates due to cocaine dependence. ( 25262527 )
2014
23
WITHDRAWN: Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. ( 23780682 )
2013
24
Psychometric Properties of the Cannabis Abuse Screening Test in Hungarian Samples of Adolescents and Young Adults. ( 24217457 )
2013
25
Cannabis abuse in adolescence and the risk of psychosis: A brief review of the preclinical evidence. ( 23916409 )
2013
26
Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function. ( 22821384 )
2013
27
A validation of the Cannabis Abuse Screening Test (CAST) using a latent class analysis of the DSM-IV among adolescents. ( 23519957 )
2013
28
Pathways to Psychosis in Cannabis Abuse. ( 23491968 )
2013
29
Cannabis abuse is associated with better emotional memory in schizophrenia: a functional magnetic resonance imaging study. ( 23906663 )
2013
30
Monitoring of chronic Cannabis abuse: an LC-MS/MS method for hair analysis. ( 23305934 )
2013
31
Contributions of ethnicity to differential item functioning of cannabis abuse and dependence symptoms. ( 23384380 )
2013
32
Adolescent ischemic stroke associated with anabolic steroid and cannabis abuse. ( 23382306 )
2013
33
Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. ( 22907121 )
2013
34
Additive effects of childhood abuse and cannabis abuse on clinical expressions of bipolar disorders. ( 24028906 )
2013
35
Alcohol and cannabis abuse/dependence symptoms and life satisfaction in young adulthood. ( 21733007 )
2012
36
Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox. ( 22716154 )
2012
37
Validation of the Cannabis Abuse Screening Test in a sample of cannabis inpatients. ( 22472963 )
2012
38
Cannabis abuse and vulnerability to psychosis: targeting preventive services. ( 22239586 )
2012
39
Bilateral testicular self-castration due to cannabis abuse: a case report. ( 21861879 )
2011
40
The validity of DSM-IV cannabis abuse and dependence criteria in adolescents and the value of additional cannabis use indicators. ( 21205060 )
2011
41
Effects of handedness (left vs right) and cannabis abuse on intermanual coordination and negative symptoms in schizophrenic patients of the paranoid type. ( 21082479 )
2011
42
Psychometric properties of the Cannabis Abuse Screening Test (CAST) in a French sample of adolescents. ( 20869178 )
2011
43
Developmental pathways to adolescent cannabis abuse and dependence: child maltreatment, emerging personality, and internalizing versus externalizing psychopathology. ( 21534646 )
2011
44
Psychometric modeling of cannabis initiation and use and the symptoms of cannabis abuse, dependence and withdrawal in a sample of male and female twins. ( 21507586 )
2011
45
Cannabis abuse and severity of psychotic and affective disorders in Israeli psychiatric inpatients. ( 19932824 )
2010
46
From child maltreatment to adolescent cannabis abuse and dependence: a developmental cascade model. ( 20883588 )
2010
47
Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse. ( 20600341 )
2010
48
Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse. ( 19997844 )
2010
49
Cannabis abuse and addiction: a contemporary literature review. ( 19630315 )
2009
50
Pathways to cannabis abuse: a multi-stage model from cannabis availability, cannabis initiation and progression to abuse. ( 19207351 )
2009

Variations for Cannabis Abuse

Expression for Cannabis Abuse

Search GEO for disease gene expression data for Cannabis Abuse.

Pathways for Cannabis Abuse

Pathways related to Cannabis Abuse according to GeneCards Suite gene sharing:

(show all 11)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.99 CHRNA3 CHRNA5 CHRNB3 CNR1 CNR2
2
Show member pathways
12.84 BDNF CHRNA3 CHRNA5 NGF
3
Show member pathways
12.4 BDNF CHRNA3 CHRNA5 CHRNB3 NGF
4 11.49 BDNF CNR1 NGF
5
Show member pathways
11.42 BDNF NGF
6 11.38 BDNF NGF
7
Show member pathways
11.25 BDNF NGF
8
Show member pathways
11.19 BDNF NGF
9
Show member pathways
11.05 CNR1 CNR2
10
Show member pathways
10.73 CHRNA3 CHRNA5 CHRNB3
11 10.7 CNR1 CNR2

GO Terms for Cannabis Abuse

Cellular components related to Cannabis Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.33 CHRNA3 CHRNA5 CHRNB3
2 postsynaptic membrane GO:0045211 9.13 CHRNA3 CHRNA5 CHRNB3
3 acetylcholine-gated channel complex GO:0005892 8.8 CHRNA3 CHRNA5 CHRNB3

Biological processes related to Cannabis Abuse according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.91 CHRNA3 CHRNA5 CHRNB3 CNR1 CNR2
2 cation transmembrane transport GO:0098655 9.54 CHRNA5 CHRNB3
3 sensory perception of pain GO:0019233 9.52 CNR1 CNR2
4 excitatory postsynaptic potential GO:0060079 9.5 CHRNA3 CHRNA5 CHRNB3
5 regulation of postsynaptic membrane potential GO:0060078 9.49 CHRNA5 CHRNB3
6 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.48 CNR1 CNR2
7 neuromuscular synaptic transmission GO:0007274 9.46 CHRNA5 CHRNB3
8 negative regulation of nitric-oxide synthase activity GO:0051001 9.43 CNR1 CNR2
9 behavioral response to nicotine GO:0035095 9.4 CHRNA3 CHRNA5
10 negative regulation of mast cell activation GO:0033004 9.37 CNR1 CNR2
11 negative regulation of action potential GO:0045759 9.26 CNR1 CNR2
12 cannabinoid signaling pathway GO:0038171 9.16 CNR1 CNR2
13 response to nicotine GO:0035094 9.13 CHRNA5 CHRNB3 CNR1
14 synaptic transmission, cholinergic GO:0007271 8.8 CHRNA3 CHRNA5 CHRNB3

Molecular functions related to Cannabis Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular ligand-gated ion channel activity GO:0005230 9.43 CHRNA3 CHRNA5 CHRNB3
2 drug binding GO:0008144 9.4 CHRNB3 CNR1
3 acetylcholine receptor activity GO:0015464 9.37 CHRNA3 CHRNA5
4 ligand-gated ion channel activity GO:0015276 9.33 CHRNA3 CHRNA5 CHRNB3
5 cannabinoid receptor activity GO:0004949 9.32 CNR1 CNR2
6 acetylcholine binding GO:0042166 9.13 CHRNA3 CHRNA5 CHRNB3
7 acetylcholine-gated cation-selective channel activity GO:0022848 8.8 CHRNA3 CHRNA5 CHRNB3

Sources for Cannabis Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....